SCHEMBL8022326

SCHEMBL8022326

Cc1ccccc1C1=Nc2ccccc2Sc2ccccc21

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
DRD2 P14416 3/20 0.43
CNR1 P21554 3/20 0.38
CNR2 P34972 1/20 0.38
LMNA P02545 1/20 0.37
CHRM2 P08172 1/20 0.37
HTR1A P08908 1/20 0.37
ADRA2A P08913 1/20 0.37
CHRM1 P11229 1/20 0.37
ADRA2B P18089 1/20 0.37
ADRA2C P18825 1/20 0.37
CHRM3 P20309 1/20 0.37
DRD1 P21728 1/20 0.37
SLC6A2 P23975 1/20 0.37
HTR2A P28223 1/20 0.37
HTR2C P28335 1/20 0.37
SLC6A4 P31645 1/20 0.37
ADRA1A P35348 1/20 0.37
HRH1 P35367 1/20 0.37
OPRM1 P35372 1/20 0.37
DRD3 P35462 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8022153 0.80 CNR1 (0.46) DRD2CNR1CNR2LMNACHRM2
SCHEMBL5443827 0.79 IDO1 (0.50) DRD2CNR1LMNACHRM2HTR1A
SCHEMBL85731 0.78 DRD2 (0.47) DRD2LMNACHRM2HTR1AADRA2A
SCHEMBL1132787 0.74 USP2 (0.47) DRD2CNR1CNR2PLECRARA
SCHEMBL88348 0.71 BACE1 (0.57) DRD2LMNACHRM2HTR1AADRA2A
SCHEMBL12844946 0.71 DRD2 (0.47) DRD2LMNACHRM2HTR1AADRA2A
SCHEMBL8470 0.71 DRD2 (0.47) DRD2LMNACHRM2HTR1AADRA2A
SCHEMBL12778506 0.71 DRD2 (0.47) DRD2LMNACHRM2HTR1AADRA2A
SCHEMBL20829220 0.71 DRD2 (0.47) DRD2LMNACHRM2HTR1AADRA2A
SCHEMBL10263717 0.70 PLEC (0.65) DRD2LMNAPLECNPC1SMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2008121415-A2 IMPROVED PROCESS FOR PREPARING QUETIAPINE FUMARATE TEVA PHARMACEUTICAL INDUSTRIES LTD. (IL) 2008-10-09 WO disclosed
US-20080241949-A1 Process for preparing quetiapine fumarate TEVA PHARMACEUTICAL INDUSTRIES LTD (IL) 2008-10-02 US disclosed
US-20080241949-A1 Process for preparing quetiapine fumarate TEVA PHARMACEUTICAL INDUSTRIES LTD (IL) 2008-10-02 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080241949-A1 Process for preparing quetiapine fumarate CYP3A5, CYP3A4, FH DRD2 465/4885CNR1 2336/4885CNR2 2585/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.